Related News
Fosun to cut stake in Indian firm
Print Edition
SHANGHAI Fosun Pharmaceutical Group has agreed to cut the size of the stake it will buy in India’s Gland Pharma to 74 percent, the Chinese drugmaker said yesterday.
It said Gland Pharma’s founding family wanted to retain a higher stake in the Indian firm because of its good performance.
Fosun had previously been targetting an 86 percent stake valued at about US$1.26 billion. It said in a statement to the stock exchange that the board had approved the new plan, which would involve investment of no more than US$1.09 billion.
The deal had earlier faced some concerns in India, a source has told Reuters.
Under the new terms, Fosun Pharma said it would spend no more than US$25 million for the Indian firm’s Enoxaparin prototype sales in the US, when it gets approval there, cutting the previously proposed amount by half.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
